China Shineway Pharmaceutical Group Limited

SEHK:2877 Voorraadrapport

Marktkapitalisatie: HK$6.6b

China Shineway Pharmaceutical Group Toekomstige groei

Future criteriumcontroles 2/6

China Shineway Pharmaceutical Group zal naar verwachting groeien in winst en omzet met respectievelijk 8.3% en 12.8% per jaar. De winst per aandeel zal naar verwachting groeien met 7.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 14.7% zijn.

Belangrijke informatie

8.3%

Groei van de winst

7.5%

Groei van de winst per aandeel

Pharmaceuticals winstgroei10.8%
Inkomstengroei12.8%
Toekomstig rendement op eigen vermogen14.7%
Dekking van analisten

Low

Laatst bijgewerkt13 Nov 2024

Recente toekomstige groei-updates

China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 31
China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Recent updates

China Shineway Pharmaceutical Group Limited's (HKG:2877) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Oct 18
China Shineway Pharmaceutical Group Limited's (HKG:2877) Price Is Right But Growth Is Lacking After Shares Rocket 27%

If EPS Growth Is Important To You, China Shineway Pharmaceutical Group (HKG:2877) Presents An Opportunity

Jun 03
If EPS Growth Is Important To You, China Shineway Pharmaceutical Group (HKG:2877) Presents An Opportunity

Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?

May 13
Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?

China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461

Apr 26
China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461

Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?

Apr 17
Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?

China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461

Mar 31
China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461

China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings

Mar 14
China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings

Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?

Jan 29
Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?

China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly

Sep 28
China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly

China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118

Sep 01
China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118

We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease

Aug 03
We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease

Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?

May 30
Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?

We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease

Mar 07
We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease

China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125

Sep 01
China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125

China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 31
China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet

Apr 07
China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet

China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.

Mar 11
China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.

Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?

Feb 18
Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?

Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?

Jan 31
Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?

Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?

Jan 13
Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?

What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?

Dec 25
What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?

We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease

Dec 10
We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease

Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years

Nov 25
Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years

Winst- en omzetgroeiprognoses

SEHK:2877 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20265,7031,3391,3231,4223
12/31/20254,9251,1807859723
12/31/20244,3261,0878771,1893
6/30/20244,2051,1051,0721,175N/A
3/31/20244,3611,0379301,054N/A
12/31/20234,517970788933N/A
9/30/20234,525926795957N/A
6/30/20234,534883801982N/A
3/31/20234,2428038911,046N/A
12/31/20223,9517239801,110N/A
9/30/20223,718651814941N/A
6/30/20223,485579648772N/A
3/31/20223,354568629738N/A
12/31/20213,224557610703N/A
9/30/20213,122453609690N/A
6/30/20213,020350608677N/A
3/31/20212,838322590658N/A
12/31/20202,656295573639N/A
9/30/20202,592382485561N/A
6/30/20202,528469397483N/A
3/31/20202,617486337426N/A
12/31/20192,706503277368N/A
9/30/20192,670520289382N/A
6/30/20192,633537301396N/A
3/31/20192,602521347465N/A
12/31/20182,570506393533N/A
9/30/20182,492516390521N/A
6/30/20182,413526388509N/A
3/31/20182,166489N/A500N/A
12/31/20171,920452N/A491N/A
9/30/20171,897474N/A588N/A
6/30/20171,873496N/A685N/A
3/31/20171,933542N/A709N/A
12/31/20161,993589N/A734N/A
9/30/20161,935569N/A709N/A
6/30/20161,877549N/A685N/A
3/31/20161,966603N/A715N/A
12/31/20152,055658N/A745N/A
9/30/20152,147672N/A723N/A
6/30/20152,239685N/A701N/A
3/31/20152,234695N/A737N/A
12/31/20142,229705N/A773N/A
9/30/20142,228704N/A740N/A
6/30/20142,227703N/A706N/A
3/31/20142,207693N/A613N/A
12/31/20132,187684N/A520N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 2877 ( 8.3% per jaar) ligt boven de spaarquote ( 2.3% ).

Winst versus markt: De winst van 2877 ( 8.3% per jaar) zal naar verwachting langzamer groeien dan de markt Hong Kong ( 11.5% per jaar).

Hoge groeiwinsten: De winst van 2877 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 2877 ( 12.8% per jaar) zal naar verwachting sneller groeien dan de markt Hong Kong ( 7.8% per jaar).

Hoge groei-inkomsten: De omzet van 2877 ( 12.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 2877 zal naar verwachting over 3 jaar laag zijn ( 14.7 %).


Ontdek groeibedrijven